Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors

Malignant rhabdoid tumors (MRTs) are rare and highly aggressive pediatric cancers with no standard of care. MRTs are characterized by loss of SMARCB1, which results in upregulated expression of enhancer of zeste homolog 2 (EZH2), which is responsible for the methylation of lysine 27 of histone H3 (H...

Descripció completa

Dades bibliogràfiques
Autors principals: Haruka Shinohara, Rie Sawado, Makoto Nakagawa, Ayuna Hattori, Kazutsune Yamagata, Kimiharu Tauchi, Jumpei Ito, Yasumichi Kuwahara, Tsukasa Okuda, Chitose Ogawa, Issay Kitabayashi
Format: Article
Idioma:English
Publicat: Elsevier 2022-12-01
Col·lecció:Molecular Therapy: Oncolytics
Matèries:
EZH1
EZH2
H3K27me3
malignant rhabdoid tumors (MRTs)
epigenetic drug
rare cancers
Accés en línia:http://www.sciencedirect.com/science/article/pii/S2372770522001188

Internet

http://www.sciencedirect.com/science/article/pii/S2372770522001188

Ítems similars